Поражение легких при системных заболеваниях соединительной ткани у детей
Аннотация
Поражение легких при системных заболеваниях соединительной ткани у детей — редкая патология, которая, однако, оказывает существенное влияние на выбор терапевтической тактики и прогноз. В статье представлены данные о частоте, сроках развития, спектре клинических проявлений и результатах визуализирующих методов обследования при поражении легких у детей с такими системными заболеваниями соединительной ткани, как системная склеродермия, ювенильный дерматомиозит, системная красная волчанка и синдром Шегрена. Рассматриваются вопросы патогенеза, возможные факторы риска развития поражения легких, терапевтические подходы и прогноз.
Об авторах
М. И. Каледа
Научно-исследовательский институт ревматологии им. В.А. Насоновой
Россия
Конфликт интересов:
Россия
Каледа Мария Игоревна - кандидат медицинских наук, старший научный сотрудник лаборатории ревматических заболеваний детского возраста с реабилитационной группой.
115522, Москва, Каширское ш., д. 34а, тел.: +7 (495) 109-29-10
Конфликт интересов:
Авторы статьи подтвердили отсутствие конфликта интересов, о котором необходимо сообщить
С. О. Салугина
Научно-исследовательский институт ревматологии им. В.А. Насоновой
Россия
Конфликт интересов:
Россия
115522, Москва, Каширское ш., д. 34а, тел.:+7 (495) 109-29-10
Конфликт интересов:
Авторы статьи подтвердили отсутствие конфликта интересов, о котором необходимо сообщить
Е. С. Фёдоров
Научно-исследовательский институт ревматологии им. В.А. Насоновой
Россия
Конфликт интересов:
Россия
115522, Москва, Каширское ш., д. 34а, тел.:+7 (495) 109-29-10
Конфликт интересов:
Авторы статьи подтвердили отсутствие конфликта интересов, о котором необходимо сообщить
Л. П. Ананьева
Научно-исследовательский институт ревматологии им. В.А. Насоновой
Россия
Конфликт интересов:
Россия
115522, Москва, Каширское ш., д. 34а, тел.:+7 (495) 109-29-10
Конфликт интересов:
Авторы статьи подтвердили отсутствие конфликта интересов, о котором необходимо сообщить
Список литературы
1. Ревматология. Российские клинические рекомендации / под ред. Е.Л. Насонова. М.: ГЭОТАР-Медиа; 2017.
2. Ha YJ, Lee YJ, Kang EH. Lung Involvements in Rheumatic Diseases: Update on the Epidemiology, Pathogenesis, Clinical Features, and Treatment. Biomed Res Int. 2018;2018:6930297. doi: 10.1155/2018/6930297
3. Textbook of Pediatric Rheumatology. Petty RE, Laxer RM, Lindsley CB, Wedderburn LR, eds. Philadelphia, PA: Elsiever Saunders; 2016.
4. Shiff NJ, Lix LM, Joseph L, et al. The prevalence of systemic autoimmune rheumatic diseases in Canadian pediatric populations: administrative database estimates. Rheumatol Int. 2015;35(3): 569-573. doi: 10.1007/s00296-014-3136-6
5. Denardo BA, Tucker LB, Miller LC, et al. Demography of a regional pediatric rheumatology patient population. Affiliated Children's Arthritis Centers of New England. J Rheumatol. 1994;21(8):1553-1561.
6. Patra PK, Kumar M. Clinico-epidemiological profile of pediatric rheumatology disorders in Eastern India. J Nat Sci Biol Med. 2018; 9(1):19-22. doi: 10.4103/jnsbm.JNSBM_80_17
7. Rosenberg AM. Longitudinal analysis of a pediatric rheumatology clinic population. J Rheumatol. 2005;32(10):1992-2001.
8. Dell SD, Schneider R. Chapter 57: Pulmonary involvement in the systemic inflammatory diseases of childhood. In: Kendig and Chernick’s disorders of the respiratory tract in children. Wilmott RW, Kendig EL, Boat TF, et al., eds. USA: Saunders Elsevier; 2012. pp. 822-847.
9. Okong'o LO, Scott C. The spectrum of paediatric rheumatic diseases in two tertiary centres in Cape Town, South Africa. Pediatr Rheumatol Online J. 2014;12(Suppl 1):155. doi: 10.1186/1546-0096-12-S1-P155
10. Furia FF, Godfrey E, Mwamanenge N, et al. Spectrum of paediatric rheumatic disorders at a tertiary hospital in Tanzania. Pediatr Rheumatol. 2020;18:30. doi: 10.1186/s12969-020-0418-2
11. Fischer A, du Bois R. Interstitial lung disease in connective tissue disorders. Lancet. 2012;380(9842):689-698. doi: 10.1016/S0140-6736(12)61079-4
12. Jee AS, Adelstein S, Bleasel J, et al. Role of Autoantibodies in the Diagnosis of Connective-Tissue Disease ILD (CTD-ILD) and Interstitial Pneumonia with Autoimmune Features (IPAF). J Clin Med. 2017;6(5):51. doi: 10.3390/jcm6050051
13. Nathan N, Corvol H, Amselem S, Clement A. Biomarkers in Interstitial lung diseases. Paediatr Respir Rev. 2015;16(4): 219-224. doi: 10.1016/j.prrv.2015.05.002
14. Glasser SW, Hardie WD, Hagood JS. Pathogenesis of Interstitial Lung Disease in Children and Adults. Pediatr Allergy Immunol Pulmonol. 2010;23(1):9-14. doi: 10.1089/ped.2010.0004
15. Myler HA, West JL. Heparanase and platelet factor-4 induce smooth muscle cell proliferation and migration via bFGF release from the ECM. J Biochem. 2002;131(6):913-922. doi: 10.1093/oxfordjournals.jbchem.a003182
16. Nicholson AG, Kim H, Corrin B, et al. The value of classifying interstitial pneumonitis in childhood according to defined histological patterns. Histopathology. 1998;33(3):203-211. doi: 10.1046/j.1365-2559.1998.00488.x
17. Бойцова Е.В., Овсянников Д.Ю., Беляшова М.А. Педиатрические интерстициальные заболевания легких: дети не маленькие взрослые // Педиатрия. Журнал им. Г.Н. Сперанского. — 2015. — Т. 94. — №4. — С. 171-176.
18. Rovira E, Cuadras A, Aguilar X, et al. Asthma, respiratory symptoms and lung function in children living near a petrochemical site. Environ Res. 2014;133:156-163. doi: 10.1016/j.envres.2014.05.022
19. Cottin V. Idiopathic interstitial pneumonias with connective tissue diseases features: A review. Respirology. 2016;21(2): 245-258. doi: 10.1111/resp.12588
20. Kumar A, Khan U, Shrestha B, et al. Interstitial lung disease as initial manifestation of systemic lupus erythematosus. J Nepal Health Res Counc. 2013;11(23):83-85. doi: 10.33314/jnhrc.v0i0.358
21. Çiftçi E, Yalgnkaya F, ince E, et al. Pulmonary involvement in childhood-onset systemic lupus erythematosus: a report of five cases. Rheumatology. 2004;43(5):587-591. doi: 10.1093/rheumatology/keh120
22. Tarvin SE, O'Neil RM. Systemic Lupus Erythematosus, Sjogren Syndrome and Mixed Connective Tissue Disease in Children and Adolescents. Pediatr Rheumatol North Am. 2018;65(4):711-738. doi: 10.1016/j.pcl.2018.04.001
23. El-Shahawy EE-D, Morsy AF, Algoubashy AA, et al. Pleuropulmonary manifestations in juvenile onset systemic lupus erythematosus: assessment by pulmonary function tests and multidetector computed tomography. Egyptian Rheumatologist. 2011;33(4): 163-169. doi: 10.1016/j.ejr.2011.06.001
24. Kurland G, Deterding RR, Hagood JS, et al. An official American Thoracic Society clinical practice guideline: classification, evaluation, and management of childhood interstitial lung disease in infancy. Am J Respir Crit Care Med. 2013;188(3):376-394. doi: 10.1164/rccm.201305-0923ST
25. Bush A, Cunningham S, de Blic J, et al. European protocols for the diagnosis and initial treatment of interstitial lung disease in children. Thorax. 2015;70(11):1078-1084. doi: 10.1136/thoraxjnl-2015-207349
26. Koh DM, Hansell DM. Computed tomography of diffuse interstitial lung disease in children. Clin Radiol. 2000;55(9):659-667. doi: 10.1053/crad.2000.0490
27. Guillerman RP. Imaging of Childhood Interstitial Lung Disease. Pediatr Allergy Immunol Pulmonol. 2010;23(1):43-68. doi: 10.1089/ped.2010.0010
28. Panigada S, Ravelli A, Silvestri M, et al. HRCT and pulmonary function tests in monitoring of lung involvement in juvenile systemic sclerosis. Pediatr Pulmonol. 2009;44(12):1226-1234. doi: 10.1002/ppul.21141
29. Valeur NS, Stevens AM, Ferguson MR, et al. Multimodality thoracic imaging of juvenile systemic sclerosis: emphasis on clinical correlation and high resolution CT of pulmonary fibrosis. AJR Am J Roentgenol 2015;204(2):408-422. doi: 10.2214/AJR.14.12461
30. Martini G, Foeldvari I, Russo R, et al. Systemic sclerosis in childhood: clinical and immunologic features of 153 patients in an international database. Arthritis Rheum. 2006;54(12):3971-3978. doi: 10.1002/art.222073
31. Martini G, Vittadello F, Kasapçopur O, et al. Factors affecting survival in juvenile systemic sclerosis. Rheumatology (Oxford). 2009;48(2):119-122. doi: 10.1093/rheumatology/ken388
32. Misra R, Singh G, Aggarwal P Aggarwal A. Juvenile onset systemic sclerosis: a single center experience of 23 cases from Asia. Clin Rheumatol. 2007;26(8):1259-1262. doi: 10.1007/s10067-006-0483-z
33. Adrovic A, Şahin S, Barut K, Kasapçopur Ö. Juvenile Scleroderma: A Referral Center Experience. Arch Rheumatol. 2018;33(3): 344-351. doi: 10.5606/ArchRheumatol.2018.6578
34. Foeldvari I, Tyndall A, Zulian F, et al. Juvenile and young adult-onset systemic sclerosis share the same organ involvement in adulthood: data from the EUSTAR database. Rheumatology (Oxford). 2012;51(10):1832-1837. doi: 10.1093/rheumatology/kes144
35. Russo RA, Katsicas MM. Clinical characteristics of children with Juvenile Systemic Sclerosis: follow-up of 23 patients in a single tertiary center. Pediatr Rheumatol Online J. 2007;5:6. doi: 10.1186/1546-0096-5-6
36. Baildam EM, Ennis H, Foster HE, et al. Influence of childhood scleroderma on physical function and quality of life. J Rheumatol. 2011; 38(1):167-173. doi: 10.3899/jrheum.100447
37. Guillot L, Flamein F, Thouvenin G, et al. BAL fluid surfactant protein C level is related to parenchymal lung disease in children with sarcoidosis. Chest. 2011;140(4):1104-1105. doi: 10.1378/chest.11-0681
38. Kilinc AA, Arslan A, Yildiz M, et al. Serum KL-6 level as a biomarker of interstitial lung disease in childhood connective tissue diseases: a pilot study. Rheumatol Int. 2020;40(10):1701-1706. doi: 10.1007/s00296-019-04485-4
39. Kishaba T, McGill R, Nei Y, et al. Clinical characteristics of derma-tomyosits/polymyositis associated interstitial lung disease according to the autoantibody. J Med Invest. 2018;65(3.4):251-257. doi: 10.2152/jmi.65.251
40. Morgenthau AS, Padilla ML. Spectrum of fibrosing diffuse parenchymal lung disease. Mt Sinai J Med. 2009;76(1):2-23. doi: 10.1002/msj.20087
41. Vij R, Strek ME. Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest. 2013;143(3): 814-824. doi: 10.1378/chest.12-0741
42. Sanner H, Aalokken TM, Gran JT, et al. Pulmonary outcome in juvenile dermatomyositis: a case-control study. Ann Rheum Dis. 2011;70(1):86-91. doi: 10.1136/ard.2010.131433
43. Wu Q, Wedderburn LR, McCann LJ. Juvenile dermatomyositis: Latest advances. Best Pract Res Clin Rheumatol. 2017;31(4): 535-557. doi: 10.1016/j.berh.2017.12.003
44. Fujisawa T, Hozumi H, Kono M, et al. Prognostic Factors for Myositis-Associated Interstitial Lung Disease. PLoS One. 2014; 9(6):e98824. doi: 10.1371/journal.pone 0098824
45. Bai Y Tao XN. Research progress on amyopathic dermatomyositis associated with interstitial lung disease. Chin Med J (Engl). 2020; 133(1):111-113. doi: 10.1097/CM9.0000000000000574
46. Ye Y Fu Q, Wang R, et al. Serum KL-6 level is a prognostic marker in patients with anti- MDA5 antibody-positive dermato-myositis associated with interstitial lung disease. J Clin Lab Anal. 2019;33(8):e22978. doi.org/10.1002/jcla.22978
47. Fathi M, Lundberg IE, Tornling G. Pulmonary complications of polymyositis and dermatomyositis. Semin Respir Crit Care Med. 2007 Aug;28(4):451-8. doi: 10.1055/s-2007-985666
48. Dubois’ Lupus Erythematosus and Related Syndromes. 9th ed. Wallace DJ, Hahn BH, eds. Elsiever; 2019. 816 p. doi: 10.1016/C2015-0-06776-4
49. Quadrelli SA, Alvarez C, Arce SC, et al. Pulmonary involvement of systemic lupus erythematosus: analysis of 90 necropsies. Lupus. 2009;18(12):1053-1060. doi: 10.1177/0961203309106601
50. Groot N, Graeff ND, Avcin T, et al. European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative. Ann Rheum Dis. 2017;76(11):1788-1796. doi: 10.1136/annrheumdis-2016-210960
51. Клюквина Н.Г., Асеева Е.А., Никонорова Н.О. Поражение легких при системной красной волчанке: хорошо известные факты и нерешенные вопросы // Научно-практическая ревматология. — 2016. — Т. 54. — № 5. — С. 578-589. doi: 10.14412/1995-4484-2016-578-589
52. Wallace B, Vummidi D, Khanna D. Management of connective tissue diseases associated interstitial lung disease: a review of the published literature. Curr Opin Rheumatol. 2016; 28(3):236-245. doi: 10.1097/BOR.0000000000000270
53. Alperin JM, Ortiz-Fernandez L, Sawalha AH. Monogenic Lupus: A Developing Paradigm of Disease. Front Immunol. 2018;9:2496. doi: 10.3389/fimmu.2018.02496
54. Mina R, Brunner HI. Update on differences between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Res Ther. 2013;15(4):218. doi: 10.1186/ar4256
55. Hiraki LT, Benseler SM, Tyrrell PN, et al. Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr. 2008;152(4): 550-556. doi: 10.1016/j.jpeds.2007.09.019
56. Sjogren’s syndrome. Wan-Fai NG, ed. Glasgow, UK: Oxford Unversity Press; 2016. 126 p.
57. Tomiita M, Saito K, Kohno Y et al. The clinical features of Sjogren's syndrome in Japanese children. Acta Paediatr Jpn. 1997; 39(2):268-272. doi: 10.1111/j.1442-200x.1997.tb03597.x
58. Singer NG, Tomanova-Soltys I, Lowe R. Sjogren's syndrome in childhood. Curr Rheumatol Rep. 2008;10(2):147-155. doi: 10.1007/s11926-008-0026-5
59. Yokogawa N, Lieberman SM, Sherry DD, Vivino FB. Features of childhood Sjogren's syndrome in comparison to adult Sjogren's syndrome: considerations in establishing child-specific diagnostic criteria. Clin Exp Rheumatol. 2016;34(2):343-351.
60. Virdee S., Greenan-Barrett J., Ciurtin C. A systematic review of primary Sjogren's syndrome in male and paediatric populations. Clin Rheumatol. 2017;36(10):2225-2236. doi: 10.1007/s10067-017-3745-z
61. Yazisiz V, Arslan G, Ozbudak IH, et al. Lung involvement in patients with primary Sjogren's syndrome: what are the predictors? Rheumatol Int. 2010;30(10):1317-1324. doi: 10.1007/s00296-009-1152-8
62. Palm O, Garen T, Berge Enger T, et al. Clinical pulmonary involvement in primary Sjogren's syndrome: prevalence, quality of life and mortality: a retrospective study based on registry data. Rheumatology (Oxford). 2013;52(1):173-179. doi: 10.1093/rheumatology/kes311
63. Parambil JG, Myers JL, Lindell RM, et al. Interstitial lung disease in primary Sjogren syndrome. Chest. 2006;130(5):1489-1495. doi: 10.1378/chest.130.5.1489
64. Ramos-Casals M, Brito-Zeron P, Font J. The overlap of Sjogren's syndrome with other systemic autoimmune diseases. Semin Arthritis Rheum. 2007;36(4):246-255. doi: 10.1016/j.semarthrit.2006.08.007
65. La Torre F, Martini G, Russo R, et al. A preliminary disease severity score for juvenile systemic sclerosis. Arthritis Rheum. 2012;64(12):4143-4150. doi: 10.1002/art.34652
66. Hoffmann-Vold A-M, Maher TM, Philpot EE, et al. The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statement. Lancet. 2020;2(2):E71-E83. doi: 10.1016/S2665-9913(19)30144-4
67. Distler O, Highland KB, Gahlemann M, et al. Nintedanib in systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380(26):2518-2528. doi: 10.1056/NEJMoa1903076
68. Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019; 381(18):1718-1727. doi: 10.1056/NEJMoa1908681
69. Glasser SW, Hagood JS, Wong S, et al. Mechanisms of Lung Fibrosis Resolution. Am J Pathol. 2016;186(5):1066-1077. doi: 10.1016/j.ajpath.2016.01.018
70. Ferraro VA, Zanconato S, Zamunaro A, Carraro S. Children's Interstitial and Diffuse Lung Diseases (ChILD) in 2020. Children (Basel). 2020;7(12):280. doi: 10.3390/children7120280
71. Deterding RR, DeBoer EM, Cidon MJ, et al. Approaching Clinical Trials in Childhood Interstitial Lung Disease and Pediatric Pulmonary Fibrosis. Am J Respir Crit Care Med. 2019;200(10):1219-1227. doi: 10.1164/rccm.201903-0544CI
72. Boehringer Ingelheim. A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD). April 9, 2021. Available online: https://clinicaltrials.gov/ct2/show/ NCT04093024. Accessed on April 14, 2021.
73. Легочная гипертензия у детей: клинические рекомендации. 2017. Доступно по: https://legalacts.ru/doc/klinicheskie-reko-mendatsii-legochnaja-gipertenzija-u-detei-utv-minzdravom-rossii. Ссылка активна на 14.04.2021.
При поддержке: Не указан
Для цитирования:
Каледа М.И., Салугина С.О., Фёдоров Е.С., Ананьева Л.П. Поражение легких при системных заболеваниях соединительной ткани у детей. Вопросы современной педиатрии. 2021;20(2):134-143. https://doi.org/10.15690/vsp.v20i2.2257
For citation:
Kaleda M.I., Salugina S.O., Fedorov E.S., Ananyeva L.P. Pulmonary Involvement at Connective Tissue Systemic Diseases in Children. Current Pediatrics. 2021;20(2):134-143. (In Russ.) https://doi.org/10.15690/vsp.v20i2.2257
Просмотров: 118
Послать статью по эл. почте 
